First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer

NCT06491355 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Efficacy, Self
Safety Issues
Colo-rectal Cancer

Interventions

DRUG: mfolfox6 and hlx04 regimen and Serplulimab
DRUG: mfolfox6 and hlx04 regimen

Sponsor

Sir Run Run Shaw Hospital